The pharmaceutical preparation Femicare, which contains Progesterone, is generally utilized across several core therapeutic domains to restore hormonal balance and provide symptomatic relief, strictly focusing on conditions related to progesterone deficiency or necessity. It is commonly used to help manage menopausal symptoms and regulate the menstrual cycle.

---

This medication is applied in addressing key symptoms that interfere with daily functioning and key bodily processes. Its primary uses fall into three categories: Endometrial Protection for women receiving estrogen therapy, Hormone Support during Assisted Reproductive Technology (ART) and early pregnancy, and managing Menstrual Cycle Irregularities such as absent or unpredictable periods.

“This therapy may assist with contributing to a sense of stability when symptoms are more noticeable and supports overall comfort during hormonal shifts.”

---

Key Therapeutic Focus

Femicare is relevant for easing the overall symptom load from severe vasomotor symptoms, including frequent hot flashes and disruptive night sweats. It contributes to opposing endometrial overgrowth (hyperplasia) and is applied to help with the process of embryo implantation in specific patient groups. It is used to help manage cycle regularity and provides supportive hormonal foundation when such management is appropriate.

Quick Fact: Relief for Neuroendocrine Symptoms This therapy may assist with managing associated anxiety, tension, and sleep disturbances that are linked to hormonal fluctuations.

Regulatory References

1. NIH MedlinePlus overview of Progesterone

Who Can and Cannot Use Femicare?

Femicare, which contains Progesterone, is subject to strict eligibility rules defined by regulatory authorities. These rules determine the specific populations permitted to use the medicine under standard labeled conditions and those who are formally contraindicated.

Contraindications and Non-Eligibility

Use of Femicare is contraindicated in patients with a known or suspected hormone-dependent malignant tumour, such as breast cancer, and for those with a history of arterial or venous thromboembolism (blood clots). Patients with severe hepatic impairment or acute liver disease must also not use this medicine. Additionally, eligibility is prohibited in cases of undiagnosed abnormal genital bleeding or known hypersensitivity to any ingredient.

Restricted and Conditional Use

Population Group	Regulatory Status
Pediatric Patients	Not indicated; safety and efficacy are not established.
Older Adults (65+)	Use is not established for some indications; caution is advised.
Renal Impairment	Caution and careful monitoring are required.
Pregnancy	Contraindicated for Hormone Replacement Therapy (HRT); recommended for use in Assisted Reproductive Technology (ART) protocols.

For patients with certain conditions, such as epilepsy, migraine, asthma, diabetes mellitus, or a history of depression, close monitoring and supervision are required while using this medicine.

Interactions with other medicines and products

Femicare, which contains Progesterone, has documented interactions primarily governed by the body's metabolic pathways. Official regulatory documents classify these interactions based on pharmacokinetic and pharmacodynamic outcomes.

Metabolic Interactions and Exposure

The most significant interaction mechanism involves the CYP3A4 enzyme system. Co-administration of substances known to induce CYP3A4, such as Rifampicin, Phenytoin, and Carbamazepine, officially results in increased metabolism and reduced progesterone exposure. Conversely, strong CYP3A4 inhibitors, including Ketoconazole and Ritonavir, officially reduce progesterone clearance, leading to increased plasma concentration. The herbal product St. John's Wort is also documented as a CYP3A4 inducer that may reduce exposure.

Pharmacodynamic and Administration Constraints

Progesterone may officially modify the effect of certain therapeutic agents; for instance, it can alter the effect of coumarin anticoagulants and is documented to raise the plasma concentration of Ciclosporin. An adjustment of the anti-diabetic medication dosage may be officially required when co-administered. For the oral formulation, administration must be officially separated from food ingestion (e.g., taken at bedtime) to manage the documented increase in bioavailability. Furthermore, co-administration with other vaginal products is not officially recommended with the vaginal formulation, due to their potential to alter progesterone release and absorption.

Femicare, which contains micronized progesterone, operates as an agonist at the intracellular Progesterone Receptors (PR) present in target tissues, notably the uterus, cervix, and vagina. Following cellular entry, the lipophilic progesterone molecule binds to the cytoplasmic PR, causing a conformational change and translocation of the activated receptor complex into the cell nucleus.

In the nucleus, the progesterone-PR complex binds to specific DNA sequences known as Progesterone Response Elements (PREs) located in the promoter regions of target genes. This protein-DNA interaction modulates gene transcription, increasing or repressing the synthesis of specific messenger RNAs, which subsequently alters the cellular proteome. In the endometrium, this cascade promotes glandular differentiation, stromal decidualization, and reduces proliferation. System-level physiological modulation includes antigonadotropic effects, which occur through feedback inhibition on the hypothalamic-pituitary-ovarian axis, leading to a suppression of gonadotropin secretion.

The administration of Femicare, which contains micronized progesterone, is defined by established pharmaceutical standards to ensure standardized usage. The medicine is authorized for various systemic routes, primarily oral capsules and vaginal inserts or gels, as well as parenteral (Intramuscular/Subcutaneous) injection.

Official Administration Guidelines

Usage is highly formalized by cyclic and fixed-term schedules. For instance, in one labeled regimen for endometrial protection, the oral dose is typically 200 mg administered once daily for 12 consecutive days of a 28-day cycle. Another common labeled regimen for secondary amenorrhea involves a dose of 400 mg daily for 10 days.

Procedural constraints are strictly defined. Oral capsules must be swallowed whole and are usually directed to be taken at bedtime to align with drug delivery protocols. For populations with impaired function, official instructions require dose adjustment or state a restriction, particularly for individuals with hepatic impairment. If an oral dose is missed, standard practice involves skipping the missed dose if it is near the time for the next scheduled dose, rather than doubling up. Vaginal routes, common in Assisted Reproductive Technology (ART) support, mandate administration via the provided applicators, with usage continuing for a defined period, often up to the 10th or 12th week of gestation.

Research evidence / Overview of studies for Femicare

Progesterone, the active ingredient in Femicare, has been studied for several specific clinical uses. The available evidence comes primarily from Randomized Controlled Trials (RCTs), Systematic Reviews, and large Observational Studies. These studies focus on evaluating how Progesterone was studied for its role in specific physiological processes and research examined outcomes related to systemic or functional imbalance.

---

Evidence for Endometrial Protection in Estrogen Therapy

Research has extensively examined the role of Progesterone in post-menopausal women who are receiving estrogen-based menopausal hormone therapy (MHT). Large-scale, long-term studies, which track women over several years, were used in research exploring the physiological state of the uterine lining (endometrium). Researchers primarily monitored the incidence of endometrial pathology (hyperplasia or carcinoma) and measured the thickness of the uterine lining as key outcomes related to measured physiological changes.

The findings describe patterns observed where the addition of Progesterone was associated with measurements showing differences in the measured outcomes for endometrial hyperplasia when compared to estrogen-only administration. This research provides context but not individual predictions, reflecting the study requirement for progestogen use in this context.

---

Evidence for Hormone Support in Assisted Reproductive Technology (ART)

Progesterone was studied for its role as hormone support in women undergoing Assisted Reproductive Technology (ART), such as IVF (In Vitro Fertilization). The primary outcomes examined were successful pregnancy rates (clinical and live birth rates) and implantation success within specific ART cycles. The research highlights changes measured during the study period, indicating that the use of Progesterone was observed in some studies to be associated with differences in measured live birth rates when compared to placebo or no intervention in IVF cycles. Studies monitored serum hormone levels, a research approach used to evaluate luteal phase hormone status during the early stages of pregnancy.

---

Evidence for Managing Menstrual Cycle and Related Symptoms

Menstrual Cycle Regularity

Progesterone was evaluated in women experiencing conditions characterized by fluctuating or episodic manifestations, such as irregular or absent menstrual periods. Research examined cycle patterns, focusing on outcomes related to systemic or functional imbalance and the assessment of a regular cycle pattern. The findings describe patterns observed where Progesterone administration was associated with the initiation of menstrual bleeding and measured cycle pattern outcomes in observed populations.

Vasomotor and Neuroendocrine Symptoms

Progesterone was studied for its role in managing specific menopausal outcomes related to measured physiological changes, such as hot flashes and night sweats. Research also explored patient-reported outcomes describing perceived discomfort like sleep quality, tension, and anxiety linked to hormonal shifts. Trials consistently report how symptoms evolved in the observed populations in the context of a high placebo effect—meaning participants receiving an inactive substance also reported symptom improvements.

Common questions about Femicare (FAQ)

Q: How quickly does Femicare relieve a headache?

A: Femicare typically begins working within about 15 to 30 minutes for many people, though individual responses may vary. The intended effect is generally noticeable within a short time. Official labeling commonly recommends taking Femicare with food or milk to help avoid stomach upset, and generally advises against crushing non-chewable tablets.

Q: Is it safe to take Femicare daily to prevent heart problems?

A: Low-dose Femicare is a common recommendation to help reduce the risk of certain cardiovascular events like heart attack or stroke for select patients. It is not a guaranteed preventative measure. This therapy is typically reserved for individuals with a history of cardiovascular events or those at high risk, as determined by a healthcare provider. It is essential to consult with a healthcare professional, such as a cardiologist, before starting or changing any daily Femicare regimen to determine the appropriate dosage and assess the potential risks and benefits.

Q: What happens if I accidentally take too much Femicare?

A: Symptoms of taking too much Femicare can vary, but may include ringing in the ears (tinnitus), dizziness, or stomach upset. If an accidental overdose is suspected, it is critical to seek immediate medical attention by contacting a Poison Control Center or visiting an emergency room.

Storage and Disposal of Femicare (Progesterone Capsules)

Storage Scope	Requirements Defined by Regulators
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) [^1.1].
Protection	Keep the capsules away from excess heat, moisture, and direct light [^1.5]. Do not freeze [^1.5].
Container/Safety	Must be stored in a tightly closed, original container and kept out of the sight and reach of children [^1.5].
Disposal	Do not flush or dispose of in household trash unless no take-back program is available [^2.3].

Regulatory guidance directs that unused or expired medicine should be returned via an official drug take-back program [^3.5]. If a take-back option is unavailable, the product must be mixed with an undesirable substance, sealed in a container, and placed in the trash [^3.5]. Before discarding the packaging, scratch out all personal information to protect privacy [^3.5].